|
clinical parameters
|
total
|
Number of recurrence
|
Univariate analysis
|
multivariate analysis
|
|---|
|
HR (95% CI)
|
p-value
|
Adjusted HR (95% CI)
|
p-value
|
|---|
|
age (year)
|
38.49 ± 11.10
|
30
|
1.00 (0.96~1.03)
|
0.769
|
0.99 (0.95~1.03)
|
0.541
|
|
sex
|
|
Male
|
91
|
19
|
1.00
| |
1.00
| |
|
Female
|
72
|
11
|
0.68 (0.32~1.42)
|
0.302
|
0.86 (0.39~1.93)
|
0.717
|
|
Companacci stage
|
|
I-II stage
|
86
|
6
|
1.00
| |
1.00
| |
|
III stage
|
77
|
24
|
5.95 (2.42~14.63)
|
< 0.001
|
3.28 (1.24~8.69)
|
0.017
|
|
surgical method
|
|
expanded curettage
|
94
|
17
|
1.00
| | | |
|
extensive resection
|
69
|
13
|
1.15 (0.56~2.37)
|
0.708
| | |
|
tumor diameter (cm)
|
5 (4~7)
|
30
|
1.12 (0.93~1.36)
|
0.234
| | |
|
ALP(U/L)
|
79 (63~122)
|
30
|
1.01 (1.00~1.01)
|
0.026
|
1.00 (0.99~1.00)
|
0.284
|
|
white blood cell (109/L)
|
6.03 (5.12~7.06)
|
30
|
1.08 (0.84~1.39)
|
0.539
| | |
|
ESR (mm/h)
|
17 (9~34)
|
30
|
1.01 (0.99~1.03)
|
0.232
| | |
|
CRP (mg/L)
|
8.16 (3.77~13.57)
|
30
|
1.02 (1.01~1.03)
|
0.004
|
1.02 (0.99~1.04)
|
0.199
|
|
NLR
|
|
LNLR
|
113
|
10
|
1.00
| |
1.00
| |
|
HNLR
|
50
|
20
|
5.90 (2.75~12.67)
|
< 0.001
|
4.18 (1.83~9.57)
|
0.001
|
|
PLR
|
|
LPLR
|
90
|
9
|
1.00
| |
1.00
| |
|
HPLR
|
73
|
21
|
3.17 (1.45~6.92)
|
0.004
|
2.15 (0.90~5.14)
|
0.084
|
- HR, hazard ratio; CI, confidence interval; ALP, alkaline phosphatase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LNLR, low NLR; HNLR, high NLR; LPLR, low PLR; HPLR, high PLR
